Cephalon, Inc.

Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Schering-plough Corporation

Scheeing Corporation

Pharmacopeia Inc.

Rong-qiang Liu

Neng-Yang Shih

Robert G Aslanian

Kevin D McCormick

Christopher W Boyce

Chia-Yu Huang

Bo Liang

Bruce D Dorsey

Koc-Kan Ho

Pietro Mangiaracina

Tao Guo

Henry Joseph Breslin

Younong Yu

Gregory R Ott

Rabindranath Tripathy

Craig A Zificsak

James L Diebold

Manuel De Lera Ruiz

Diane E Gingrich

Karen L Milkiewicz

Keith S Learn

Eugen F Mesaros

Benjamin J Dugan

Theodore L Underiner

Salem Fevrier

Gregory J Wells

Joseph Lisko

Gulzar Ahmed

Jay P Theroff

Matthew A Curry

Ruiyan Liu

Tho V Thieu

Jason Burke

Lisa Guise-Zawacki

Daming Feng

Purakkattle J Biju

Junying Zheng

Linda Weinberg

Huagang Lu

Jason C Wagner

Ming You

Joseph G Lisko

Jonathan Parrish

Karen Milkiewicz

Adolph Bohnstedt

Pietro Mangiarcina

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders. 

Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

ALPHA2C adrenoreceptor agonists

In its many embodiments, the present invention provides a novel class of indolines as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

&#x3b1;2C adrenoreceptor agonists

Growing community of inventors

Kendall Park, NJ, United States of America

Rong-qiang Liu